Henry Schein Names Frederick M. Lowery as Chief Executive Officer Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence MELVILLE, N.Y.

Henry Schein Names Frederick M. Lowery as Chief Executive Officer

Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence

MELVILLE, N.Y., January 12, 2026 - Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare

solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of

Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition.

Mr. Lowery brings more than two decades of healthcare expertise to Henry Schein, with a strong track record of scaling complex businesses to drive

significant growth and sustained value creation. Most recently, he served as Executive Vice President and President, Laboratory Products and BioProduction at Thermo Fisher Scientific (NYSE: TMO), leading the Fisher Scientific distribution

channel's above-market performance. His experience growing distribution and owned product businesses - including manufacturing, R&D, marketing, and sales functions - closely aligns with Henry Schein's business model,

positioning him well to guide the Company's next phase of growth and continued execution of its BOLD+1 strategic plan.

"I am honored to join

Henry Schein at such a pivotal moment. This is an organization with immense potential to impact clinicians and patients, given its remarkable reputation for innovation, customer service, and partnership," said Mr. Lowery. "I look

forward to working with Team Schein to build on the strong foundation established by Stan while accelerating value creation."

Thermo Fisher, Mr. Lowery worked in leadership roles for Maytag Corporation and General Motors. He holds a master's degree in manufacturing management from Kettering University (formerly General Motors Institute of Engineering and

Management) and a bachelor's degree in mechanical engineering from Tennessee Technological University.

"I am very pleased to welcome Fred to

Henry Schein. Beyond his extensive operational experience, he brings a leadership philosophy that reflects the values that have long defined our Company," said Mr. Bergman. "Fred understands the critical role we play in supporting

dental and medical practitioners, and he is exceptionally well equipped to lead Henry Schein into its next phase of growth."

the Board, I would like to thank Stan for his exceptional leadership and invaluable contributions over more than three decades," said Phil Laskawy, Lead Director and Chair of the Nominating and Governance Committee at Henry Schein.

"After a comprehensive search process, we are confident that Fred is the right successor to honor Henry Schein's proud heritage. With extensive commercial, logistics, and manufacturing expertise, and a focus on customer satisfaction, he

has the combination of experience and capabilities necessary to accelerate growth and value creation."

"We are excited about our strategic

partnership with Henry Schein and look forward to supporting the next chapter of the Company's journey under Fred's leadership," said Max Lin, Board Member and Vice Chair of the Nominating and Governance Committee at Henry Schein

and Partner at KKR. "We believe Fred brings a unique combination of healthcare distribution experience, operational best practices, and accountable leadership that will accelerate our strategic initiatives and further differentiate Henry

Schein as a world-class business."

Cautionary Note Regarding Forward-Looking Statements

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary

remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements

made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results,

performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

These statements are generally identified by the use of such terms as "may," "could," "expect,"

"intend," "believe," "plan," "estimate," "forecast," "project," "anticipate," "to be," "to make" or other comparable terms. A fuller

discussion of our operations, financial condition and status of litigation matters, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange

Commission, or SEC, including our Annual Report on Form 10-K, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors

that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual

results to differ materially from current and historical results include, but are not limited to: our dependence on third parties for the manufacture and supply of our products and where we manufacture products, our dependence on third parties for

raw materials or purchased components; risks relating to the achievement of our strategic growth objectives, including anticipated results of restructuring and value creation initiatives; risks related to the Strategic Partnership Agreement with KKR

Hawaii Aggregator L.P. entered into in January 2025; transitions in senior company leadership; our ability to develop or acquire and maintain and protect new products (particularly technology and specialty products) and services and utilize new

technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions and joint ventures, including the failure to achieve anticipated synergies/benefits, as well as significant demands on our

operations, information systems, legal, regulatory, compliance, financial and human resources functions in connection with acquisitions, dispositions and joint ventures; certain provisions in our governing documents that may discourage third-party

acquisitions of us; adverse changes in supplier rebates or other purchasing incentives; risks related to the sale of corporate brand products; risks related to activist investors; security risks associated with our information systems and technology

products and services, such as cyberattacks or other privacy or data security breaches (including the October 2023 incident); effects of a highly competitive (including, without limitation, competition from third-party online commerce sites) and

consolidating market; political, economic, and regulatory influences on the health care industry; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service

issues with our third-party shippers, and increases in fuel and energy costs; changes in laws and policies governing manufacturing, development and investment in territories and countries where we do business; general global and domestic

macro-economic and political conditions, including inflation, deflation, recession,

unemployment (and corresponding increase in under-insured populations), consumer confidence, sovereign debt levels, fluctuations in energy pricing and the value of the U.S. dollar as compared to

foreign currencies and changes to other economic indicators failure to comply with existing and future regulatory requirements, including relating to health care; risks associated with the EU Medical Device Regulation; failure to comply with laws

and regulations relating to health care fraud or other laws and regulations; failure to comply with laws and regulations relating to the collection, storage and processing of sensitive personal information or standards in electronic health records

or transmissions; changes in tax legislation, changes in tax rates and availability of certain tax deductions; risks related to product liability, intellectual property and other claims; risks associated with customs policies or legislative import

restrictions; risks associated with disease outbreaks, epidemics, pandemics (such as the COVID-19 pandemic), or similar wide-spread public health concerns and other natural or

man-made disasters; risks associated with our global operations; the threat or outbreak of war (including, without limitation, geopolitical wars), terrorism or public unrest (including, without limitation, the

war in Ukraine, the Israel-Gaza war and other unrest and threats in the Middle East and the possibility of a wider European or global conflict); changes to laws and policies governing foreign trade, tariffs

and sanctions or greater restrictions on imports and exports, including changes to international trade agreements and the current imposition of (and the potential for additional) tariffs by the U.S. on numerous countries and retaliatory tariffs;

supply chain disruption; litigation risks; new or unanticipated litigation developments and the status of litigation matters; our dependence on our senior management (including, without limitation, the transition to a new CEO), employee hiring and

retention, increases in labor costs or health care costs, and our relationships with customers, suppliers and manufacturers; and disruptions in financial markets. The order in which these factors appear should not be construed

to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond

our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements except

About Henry Schein, Inc.

Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than

1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work

more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein

corporate brand products in our distribution centers.

A FORTUNE 500 Company and a member of the S&P

500 index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company's sales reached $12.7 billion in 2024, and

have grown at a compound annual rate of approximately 11.2 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein,

Instagram.com/HenrySchein, LinkedIn.com/Company/HenrySchein, and @HenrySchein on X.

Senior Vice President and Chief Financial

Vice President, Investor Relations and Strategic Financial Project Officer

Vice President, Global Corporate Communications